Skip to main content
. 2023 May 1;16:2611–2623. doi: 10.2147/IDR.S402585

Figure 4.

Figure 4

Using PAB on admission for predicting the prognosis of HBV‐ACLF. (a) the concentrations of PAB in Non-survivor (n = 38) and Survivor (n =82) patients in the deriving cohort. (b) ROC analysis shows the performance of PAB in distinguishing Non-survivor patients from Survivor patients in the deriving cohort.